Navigation Links
Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients

RESEARCH TRIANGLE PARK, N.C., June 18 /PRNewswire-FirstCall/ -- Lawrence D. Stern, chairman and CEO of Talecris Biotherapeutics (Nasdaq: TLCR), received the Ernst & Young Entrepreneur Of The Year® 2010 Award in the health sciences category in the Carolinas at a ceremony last night in Charlotte, N.C. The Ernst & Young awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses.

Stern was one of ten CEOs selected as a winner from among 27 finalists by a panel of independent judges composed of prominent business leaders in North Carolina.

"I am honored to accept this award on behalf of Talecris employees and the patients whose lives are saved and enhanced by the critical-care therapies we discover and produce," said Stern. "This award represents not only my own entrepreneurial vision for the company, but the immense talent, spirit and drive of the Talecris employees who have translated our vision into a reality."  

Stern led the formation of Talecris in 2005 upon acquiring the assets of a division of Bayer Corporation. From these assets, the Talecris leadership team built new systems and processes to sustain the company's long-term growth and success as a global leader in developing, manufacturing and marketing protein therapies derived from human plasma. In five years' time, the company doubled its revenue, tripled the number of employees, launched new products and expanded its global presence. In 2009, Talecris achieved record sales of $1.53 billion.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit:

About Ernst & Young's Entrepreneur Of The Year(R) Awards Program

Ernst & Young's Entrepreneur Of The Year® is the world's most prestigious business award for entrepreneurs. The award recognizes the contribution of individuals who inspire others through their vision, leadership and achievement. As the first and only global award of its kind, Ernst & Young Entrepreneur Of The Year® celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 135 cities in 50 countries.

SOURCE Talecris Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
2. Talecris Forms Partnership to Co-Promote Life-Saving Rabies Products
3. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
6. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
7. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
8. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
9. Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
10. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
11. Oxygen Biotherapeutics, Inc. to Webcast Shareholder Meeting
Post Your Comments:
(Date:11/24/2015)... , Nueva York , ... Biomedical Devices (ABD), fabricante del Avery Breathing Pacemaker ... Anders Jonzon , MD; Ph.D. como consultor clínico. ...   --> Foto - ... --> El doctor Jonzon es un fisiólogo ...
(Date:11/24/2015)... 24, 2015 --> ... Biologics Market by Product Type (Bone Graft, Bine Graft Substitute, ... Fusion, Posterior Lumbar Interbody Fusion), End User, and Geography - ... was valued at $1.90 Billion in 2014 and is expected ... 4.4% during the forecast period of 2015 to 2020. ...
(Date:11/24/2015)... FRAMINGHAM, Mass. , Nov. 24, 2015   ... leading innovator of less-invasive, miniaturized circulatory support technologies that ... announced that President and Chief Executive Officer Doug ... Jaffray 27 th Annual Healthcare Conference on December ... being held December 1-2 in New York ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA ... Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. ... traditional cutting tools, such as the scalpel and high-speed drill, which can both cause ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Charitable giving ... charitable donations are made in the last five weeks of the year totalling over ... created in 2012 to connect the nation’s charities with those individuals who want to ...
(Date:11/24/2015)... (PRWEB) , ... November 25, 2015 , ... ... technologies and development solutions for drugs, biologics, consumer health and global clinical supply ... present at the upcoming Clinical Trial Supply East Asia Conference, to be held ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Preparing for ... p.m. – 3:00 p.m. EST, , FDA has long asserted that ... regulations apply to performing the tests and do not meet the device regulations. , ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... LENR HHT Bolier Reactor System. Brillouin is the developer of renewable energy technologies ... low energy nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler ...
Breaking Medicine News(10 mins):